Med. Pro Praxi 2007; 3: 128-131

Demence - 2. část: farmakoterapie

doc. MUDr. Vladimír Pidrman Ph.D
Psychiatrická klinika FN a LF UP, Olomouc

Autor popisuje základní kroky ve farmakoterapii demencí, rozebírá účinky moderních léků a přístupů v léčbě demence. Na závěr shrnuje základní zásady v léčbě demence.

Keywords: demence, donepezil, galantamin, rivastigmin

Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pidrman V. Demence - 2. část: farmakoterapie. Med. praxi. 2007;4(3):128-131.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alexopoulos GS, Katz IR, Reynolds CF, Carpenter D, Docherty JP. Pharmacotherapy of depressive disorders in older patients. Comprehensive NeuroScience, Inc., New York, 2001: 76 s.
    2. Auriacombe S, Pere JJ, Loria-Kanza, Vellas B. Efficacy and safety of rivastigmine in patiens with Alzheimer's disease who failed to benefit from treatment with donepezil. Current Medical research and opinion vol. 18, 2002; 3: 129-138. Go to original source... Go to PubMed...
    3. Bareš M. Léčba depresivní poruchy v pozdním věku. Klin Farmakol Farm 2004; 18: 38-44.
    4. Basire S. Psychotropic drug directory 2003/04. Fivepin Publishing, Ltd., Salisbury, 2003: 416 s.
    5. Blazer DG, Steffens CD, Busse EW. Textbook of geriatric psychiatry. American Psychiatric Publishing, Inc., Washington, DC, 2004: 568 s.
    6. Bryant J, Clegg A, Nicholson T et al. Clinical and cost-effectiveness of donepezil, rivastigmin and galantamin for Alzheimer's disease: a rapid and systematic review. Health Technol Assess 2001; 5: 1-137. Go to original source... Go to PubMed...
    7. Cummings JL. The Neuropsychiatry of Alzheimer´s disease and related dementia. Martin Dunitz, London, 2003: 312 p.
    8. Doody RS, Stevens JC, Beck C et al. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154-1166. Go to original source... Go to PubMed...
    9. Gauthier S. Alzheimer´s disease. Martin Dunitz, London, 2001: 386p.
    10. Gelder MG, Lopez-Ibor JJ, Anreasen NC. New Oxford textbook of psychiatry. Oxford University Press, New York, 2003: 2432 s.
    11. Giacobini E. Cholinesterases and cholinesterase inhibitors. Martin Dunitz, 2000: 270s.
    12. Grossberg GT, Stehelin HB, Messina JC, Anand R, Veach J. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of mediacations. Int J Geriatr Psychiatry 2002; 15: 242-247. Go to original source...
    13. Helmchen H, Lauter H. Diagnostic problems in geriatric psychiatry. In: Henn F, Sartorius N, Helmchen H, Lauter H. Contemporary psychiatry. Springer, New York, 2001; 3: 117-128. Go to original source...
    14. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. UCP Supplement June 2002; 12: 45-63.
    15. Jacobson SA, Pies RW, Greenblatt DJ. Handbook of geriatric psychopharmacology. American Psychiatric Publishing, Inc. Washington, DC, 2002: 496 s.
    16. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41 (10): 719-739. Go to original source... Go to PubMed...
    17. Jirák R, Koukolík F. Demence. Neurobiologie, klionický obraz, terapie. Galén, Praha, 2004: 336 s.
    18. Maj M, Akiskal HS, Lopez-Ibor JJ, Sartorius N. Bipolar disorder. John Wiley and Sons Ltd., Chichester, 2003: 524 s. Go to original source...
    19. Maj M, Sartorius N. Dementia. John Wiley and Sons Ltd., Chichester, 2002: 398 s. Go to original source...
    20. Mesulam M, Guillozet AL, Shaw P et al. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis. 2002; 9: 88-93. Go to original source... Go to PubMed...
    21. Murray CJL, Lopez AD. The global burden of disease. Cambridge, Harvard University Press, 1996.
    22. Muller WE, Forstl H. Pharmacological and nonpharmacological approaches to the treatment of dementia. In: Henn, Sartorius, Helmchen, Lauter: Contemporary psychiatry, New York, 2001; 2: 35-46. Go to original source...
    23. Nordberg A, Darreh-Shori T, Svensson A et al. Acetylcholinesterase and butyrylcholinesterase activities in CSF of mild AD patoens following 12 months of rivastigmine treatment. J Neurol Sci 2001; 187(Suppl 1): P0144.
    24. Pidrman V. Demence - základní diferenciální diagnostika a farmakoterapie. Postgraduální medicína, příloha, 6, 2004; 3: 30-35.
    25. Pidrman V. Farmakoterapie demence. In: Růžička E et al. Diferenciální diagnostika a léčba demencí. Galén, Praha, 2003; 113-136.
    26. Qizilbash N, Schneider LS, Chui H, Tariot P et al. Evidence-based dementia practice. Blackwell Publ. Oxford, 2003; 894 s. Go to original source...
    27. Raskind MA, Peskind ER, Wessel T et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with 6-month extension. The galantamine USA-1 Study Group. Neurology 2000; 54: 2261-2268. Go to original source... Go to PubMed...
    28. Reuben BD, Herr KA, Pacala JT et al. Geriatrics. Blackwell Publishing, Inc., Malden, 2003; 240s.
    29. Siek GC, Katz LS, Fishman EB et al. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer's disease brain. Biol Psychiatry 1990; 27: 573-580. Go to original source... Go to PubMed...
    30. Schaltberg AF, Cole JO, DeBatista C. Manual of clinical psychopharmacology. American Psychiatric Publishing, Inc. Washington, DC, 2003; 700s.
    31. Stahl MS. Essential psychopharmacology. Neurocsientific basis and practical applications. Cambridge University Press, Cambridge, 2002; 602 s.
    32. Taylor D, Paton C, Kervin R. 2003 prescribing guidelines. 7th edition. Martin Dunitz, London, 2003: 272 s. Go to original source...
    33. Winblad B. Memantine and Alzheimer disease. Science Press Ltd, London, 2003: 64 s.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.